Welcome to Nofinity

• MOTS-c is a small peptide (12–40 amino acids) encoded in the mitochondrial genome.
• It is synthesized as an independent protein, not a fragment of a larger one.
• Translation likely occurs in the cytosol (not in mitochondria), because the mitochondrial code would otherwise produce a stop codon.

• MOTS-c acts as a stress communicator between mitochondria and the nucleus.
• It is released when cells are under stress (e.g., exercise, infection, nutrient deprivation).
• Primary role: metabolic reprogramming – especially regulation of lipid and cholesterol metabolism and insulin sensitivity.
• It influences protein homeostasis (e.g., in muscle during heat stress from exercise).
• MOTS-c also has antimicrobial properties (evolutionary origin from mitochondrial bacterial ancestors) and modulates the immune system (e.g., interferon pathway).

• Exercise (aerobic) increases MOTS-c in muscle and blood.
• MOTS-c alone has little effect on happy cells – it only works during persistent stress (chronic adaptation).
• In mice (human equivalent ~60–65 years old), a 2-week injection of MOTS-c made them outrun middle-aged mice – not by building muscle, but by improving stress resilience.

• MOTS-c blood levels tend to decline with age, but the ability to mount a stress response also decreases.
• MOTS-c can act as an adaptation signal: In old mice, it slowed muscle loss (sarcopenia) and reduced body fat without increasing muscle mass.
• Chronic administration (e.g., 3×/week) improved physical performance (walking test).

• A single nucleotide variant in the mitochondrial genome (common in East Asians) alters MOTS-c and increases type 2 diabetes risk – especially in men.
• Regular exercise completely eliminates this risk, likely because it lowers the baseline stress level.

• An engineered MOTS-c analog (company CohBar) reached Phase 1b (safety) with positive signals for fatty liver and obesity, but the company closed during the pandemic.
• Currently, a FDA hearing is considering whether to list MOTS-c on the 503A bulk substance list (allowing compounding pharmacies to produce it with a prescription).
• Caution: No regulatory approval exists; many users obtain MOTS-c from unverified sources (e.g., China).

• MOTS-c is a master regulator of metabolic and immune stress adaptation – not a simple on/off switch for a single disease.
• It may be particularly useful for prevention and healthy aging (sarcopenia, obesity), but approval as an anti-aging intervention is complex.
• Dr. David Lee hopes to see MOTS-c enter regulated clinical use within 3–5 years.

Note: No imperial units appeared in the transcript; all measurements are already metric.

The Federal Reserve kept rates steady for the fifth meeting, but three officials voted to hike. This unified hawkish stance echoes June 2007, when the Fed, after a 15-month pause, suddenly cut rates by 50 basis points in a panic. Historically, the median gap between the final hike and first cut is about 7.5 months—but hawkish resolve at the top is often a lagging indicator while the economy weakens underneath.

• Credit markets flashing stress: Nvidia's 5-year credit default swap hit an all-time high of 82 basis points—a massive move for the world's most profitable company. Reason: reports of potential $750 billion in AI infrastructure commitments, while balance-sheet exposure is only $3.5 billion. Oracle's CDS sits above 200 bps, Meta at 93, Alphabet at 65, and Amazon's widened to 855 bps (implying ~50% default probability within 5 years).
• Private credit defaults hit a record 6% this year. US commercial bankruptcy filings rose 13% YoY; large corporate bankruptcies reached 372 in the first half—the highest since 2010. The AI buildout is increasingly debt-funded: hyperscalers issued $244 billion in bonds through mid-July (more than double all of 2025), but investor coverage collapsed from 5x to under 2x.

• Labor market: The June jobs report showed only 57,000 payrolls (vs. 115,000 expected), with 74,000 downward revisions. The unemployment rate paradoxically fell from 4.3% to 4.2% because 720,000 people left the labor force (lowest participation since March 2021). This "low hire, low fire" scenario masks underlying weakness.
• Liquidity buffers draining: The Fed's reverse repo facility collapsed from $2.5 trillion to nearly zero. Bank reserves are at $3.1 trillion—the low end of what the Fed deems "ample." New Fed Chair Kevin Walsh (confirmed May 2024) was the 2008 crisis operator who designed emergency liquidity facilities. His Jackson Hole speech (Aug 27-29) and the FOMC meeting on Sept 16 (one day after corporate tax payments) could be pivotal.

Bitcoin is about 9.5x more sensitive to global liquidity than other assets. A likely sequence:

1. Phase 1 (Chaos): In a crisis, correlations go to 1—Bitcoin often falls first (e.g., 50% drop in March 2020).
2. Phase 2 (Rebound): Once the Fed floods the system with liquidity, Bitcoin rockets higher, outperforming stocks and gold. The turn often comes before the actual rate cut.

Current positioning: Spot Bitcoin ETFs saw their first negative half-year ever with $5.4 billion net outflows. However, long-term holders control a record 83% of supply and are accumulating 50,000-100,000 BTC per month—the strongest accumulation in 6 years.

The 30-year Treasury yield hit 5.2% (highest since 2007). If the term premium keeps rising while the Fed cuts, the liquidity impulse gets absorbed by bonds before reaching risk assets. This could invalidate the bullish thesis.

Conclusion: The Fed's hawkish pause may historically be a precursor to an imminent pivot. Credit market signals and dwindling liquidity buffers suggest a potential break. Bitcoin could dip first, then benefit disproportionately from the expected liquidity flood.

Summary follows...

• Bitcoin is trading around $63,500, caught between the 200-week moving average ($63,700) and the bear market resistance band ($69,000).
• These two levels are converging and will force a decisive move within the next few months: either a breakout above resistance or a breakdown below the 200-week MA.

• Many on-chain indicators (e.g., MVRV Z-Score) have not fully reset – pointing to a possible further decline.
• Similar setups occurred in 2014, 2018, and 2022: after a quiet summer, a sharp drop in August reset the indicators, followed by a rally.

• Historically, August is a weak month in mid-term years (e.g., −15 % in 2022, −15 % in 2018, −18 % in 2014).
• A drop of roughly 10 % would bring Bitcoin close to new lows – caution warranted.
• The window of weakness is expected to open from mid to late August.

• Short-term price moves are random – no exact timing possible.
• The tightening between the two key levels will eventually unleash higher volatility.
• For long-term holders, dollar-cost averaging remains a sound strategy.
• Note: The ITC Conference (Miami, Nov 20–22) might coincide with or closely follow the cycle bottom.

In this episode of the Huberman Lab Podcast, Dr. Max Krummel, professor of immunology and cancer biology at UC San Francisco, explains how the immune system works and how sleep, thoughts, and aging shape its function. Here are the key takeaways:

• Early life: Children get sick often because their immune system is inexperienced – it must learn to distinguish harmless from dangerous pathogens. At birth, the immune system is suppressed to prevent attacking rapidly developing tissues.
• Aging: Immune function declines not only due to cellular aging but also because of genetic mosaicism: every cell accumulates mutations, making the body increasingly “foreign.” The immune system struggles to distinguish self from non-self – analogous to WWII submarines that had to recognize engine sounds of friendly vs. enemy vessels.

• Mechanism: During sleep, immune cells migrate back to bone marrow while neutrophils deposit collagen in tissues. Sleep is a repair phase for clearing metabolic waste. Lack of sleep causes swollen lymph nodes under the eyes and increased susceptibility to infection.

• Function: The thymus produces and „educates“ T cells by showing them all self-proteins. Only cells that do not overreact to self are released.
• Aging: The thymus shrinks over time – large in children, small in adults. This may explain why older people produce fewer new T cells and become more vulnerable to cancer.

• Mobility vs. residency: Some immune cells circulate constantly, others remain tissue-resident (e.g., in skin or liver). Spatial organization is critical – similar to wound healing, where different cell layers have distinct roles.
• Transplantation: In animal studies, pancreatic cells can survive under the kidney capsule if the immune system tolerates them. This shows that context (blood supply, immune environment) is essential for tissue survival.

• Insular cortex: Studies reveal that recalling an inflammatory event (e.g., gut inflammation) can reactivate the immune response. The insular cortex stores not only emotional but also immunological states – meditation might leverage this mechanism to reduce inflammation.

• Nuance: Dr. Krummel emphasizes that vaccines save lives, but questions about timing and combination are legitimate. Protocols are often standardized for convenience, not necessarily optimal for every child.
• Autoimmune diseases: They arise when the immune system mistakenly attacks self-tissue. Genetic factors (e.g., lupus) play a role, but environmental triggers like maternal infection during pregnancy can influence neural development (a model for autism). Autoimmunity can also be beneficial: mild psoriasis might protect against certain infections.

• Prioritize sleep: Adequate sleep is essential for immune function, enabling tissue cleanup and regeneration.
• Exercise and diet: An active lifestyle and balanced diet support microbiome diversity and immune tolerance.
• Stress management: Chronic stress weakens immunity, while acute stress temporarily boosts it.

The episode concludes with a strong endorsement of basic research and the need for clear science communication – exactly what Dr. Krummel does in his Substack „The Immune Beyond“.

This video analyzes the risks and rewards of investing in major tech companies Google (GOOGL), Microsoft (MSFT), Amazon (AMZN), and Nvidia (NVDA), with a side note on Meta and Apple. The focus is on 'circular financing' in the AI sector and the associated hidden risks.

• Google (Alphabet): Despite strong cloud revenue, a large part of growth is dependent on Anthropic (40% of cloud revenue). Together with OpenAI, Anthropic accounts for roughly half of the total cloud backlog (2 trillion USD) at hyperscalers.
• Nvidia: Impressive revenue growth, but the company must finance customers to secure chip sales – a classic case of circular financing.
• Pattern: Tech giants invest around 200 billion USD annually in AI, but their main customers (OpenAI, Anthropic) are not profitable and may never be.

• Microsoft: Property, plant, and equipment rose to 313 billion USD, but depreciation (only 40 billion USD) is too low – 60 billion USD would be needed with a 5-year useful life. The cloud backlog with OpenAI stands at 625 billion USD.
• Amazon: Massive investments (170-220 billion USD over 12 months), but free cash flow turns negative. Growth heavily depends on Anthropic.
• Meta: Increases spending to 130-145 billion USD, but costs grow (55%) faster than revenue (28%). Margins shrink, and there is a lack of a direct 'circular' customer.

• Hyperscalers have hidden liabilities estimated at 1.65 trillion USD through special purpose vehicles, capacity off-takes, and leases.
• The capex-to-cloud-revenue ratio is alarming: Google 2x, Microsoft 3x, Meta even 10x – a sign of extreme reliance on circular deals.

• The speaker argues the biggest risk is not AI failing, but succeeding. Then, smarter models could drastically cut costs (e.g., 10% of current costs), questioning the entire investment logic.
• China is also investing heavily in AI and could offer a cheaper alternative – long-term, only price-performance matters.

• Apple is cited as a positive counterexample: low investments (14 billion USD), high profitability – but its P/E of 47 is also high.
• Current valuations (e.g., Alphabet at 4 trillion market cap) require unrealistic profit increases (e.g., 400 billion USD net profit in 5 years), which are mathematically hard to achieve.
• Historical parallels: The dotcom bubble and Microsoft's 15-year stock stagnation after 2000 show that such phases can last long.

The speaker rejects investments in these AI hyperscalers as too risky and prefers classic value stocks. He warns that the market is pricing in 'more than perfection', which rarely ends well historically.

📉 Key Message: AI growth is inflated by circular financing and hidden debt – investors should closely scrutinize actual profitability.